Skip to main content
Premium Trial:

Request an Annual Quote

Hologic Refinances Amended Loan and Revolving Credit Agreements

NEW YORK (GenomeWeb) – Hologic said today in a filing with the US Securities and Exchange Commission that it has inked a refinancing of an existing amended and restated credit and guaranty agreement with Bank of America and other lenders.

Under the refinancing amendment, each lender converted its commitments under the original credit agreement into new credit facilities that consist of a $1.5 billion secured term loan to Hologic maturing on Dec. 15, 2023 and a secured revolving credit facility under which the firm may borrow up to $1.5 billion, subject to certain sublimits, with the same maturity date.

Hologic noted that it has already borrowed $350 million under the revolving credit facility, and that the funds may be used to provide working capital and for other general corporate purposes.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.